Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hanjo Belz"'
Autor:
Martin Bögemann, Nguyen Tran, Philipp Spiegelhalder, Hanjo Belz, Susan Feyerabend, Christoph Rüssel, Werner Baurecht, Axel S. Merseburger, Katrin Kruetzfeldt
Publikováno v:
Aktuelle Urologie. 51:562-571
Zusammenfassung Hintergrund Abirateronacetat (AA) ist ein Prodrug von Abirateron, einem irreversiblen Inhibitor der 17α-Hydroxylase/C17, 20-lyase. Seit 2011 steht Abirateronacetat in Kombination mit Prednison/Prednisolon (AA + P) zur Therapie des me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d243d10abda9dfc743ff6f757db65332
https://doi.org/10.1055/a-1121-7593
https://doi.org/10.1055/a-1121-7593
Autor:
Marc-Oliver Grimm, Viktor Grünwald, Harald Müller-Huesmann, Philipp Ivanyi, Martin Schostak, Eyck von der Heyde, Wolfgang Schultze-Seemann, Hanjo Belz, Martin Bögemann, Meng Wang, Martin Herber, Jens Bedke
Publikováno v:
European urology focus. 8(5)
Background: Nivolumab monotherapy is approved for the treatment of advanced renal cell carcinoma (aRCC) after prior therapy on the basis of results from CheckMate 025. Objective: The NORA (NivOlumab in Renal cell cArcinoma) noninterventional study (N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d73e8eff7a081d0e66eed69574a71e08
https://pubmed.ncbi.nlm.nih.gov/34953677
https://pubmed.ncbi.nlm.nih.gov/34953677
Autor:
Axel S, Merseburger, Christoph, Rüssel, Hanjo, Belz, Philipp, Spiegelhalder, Susan, Feyerabend, Nguyen, Tran, Katrin, Kruetzfeldt, Werner, Baurecht, Martin, Bögemann
Publikováno v:
Aktuelle Urologie. 51(6)
Abiraterone acetate (AA) is a prodrug of abiraterone, which is an irreversible inhibitor of 17α-hydroxylase/C17, 20-lyase. Since 2011, abiraterone acetate has been available in combination with prednisone/prednisolone (AA + P) for the treatment of m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::104c79779b3d226141b8228f3434f0ff
https://pubmed.ncbi.nlm.nih.gov/32268436
https://pubmed.ncbi.nlm.nih.gov/32268436
Autor:
Jennifer Kranz, Richard Cathomas, Christian D. Fankhauser, Wolfgang Loidl, Werner Wosniok, Emanuela Trenti, Klaus Eredics, Carsten Bokemeyer, Hermann Reichegger, Björn Haben, Stefan Zastrow, Gazanfer Belge, Sven Peine, Jörg Sommer, Julia Heinzelbecker, Alexander Winter, Jann Frederik Cremers, Silke Gillessen, Marius Bolten, Martin Pichler, Friedemann Zengerling, Arlo Radtke, Christoph Oing, Klaus-Peter Dieckmann, Thomas Hermanns, Marcus Hentrich, Hanjo Belz, Cord Matthies, Lajos Géczi, Christian Ruf, Ulrike Eckardt, Axel Heidenreich, Anja Lorch, Petra Anheuser, Renate Pichler, Sebastian Melchior, Johannes Hammel, Susanne Krege, Christian Wülfing
Publikováno v:
Journal of Clinical Oncology
PURPOSE Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have a much higher sensitivity and specificity than the classic markers of testicular germ cell tumors (GCTs) and are applicable toward both seminoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f915aa1242f29cbe291c74f8189918
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/101762
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/101762
